Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Leiden – page 73

1 938 clinical trials in Leiden, The Netherlands across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Leiden at a glance
1 938
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 938 trials in Leiden

Open in trial search

Cystic fibrosis

Not yet recruiting

Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Vertex Pharmaceuticals Inc.

T-cell type acute leukaemia

Not yet recruiting

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Centre Hospitalier De Versailles

Rheumatoid arthritis

Not yet recruiting

ELV001 for Active Rheumatoid Arthritis in Patients with Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ELV001
  • Sponsor:Elevara Medicines Limited

Sepsis

Not yet recruiting

Anakinra for Sepsis and Hyperinflammation in Pediatric Cancer Patients in the Intensive Care Unit

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Anakinra
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Pancreatic carcinoma

Not yet recruiting

Phase II/III trial of autologous dendritic cells loaded with allogenic mesothelioma lysate in patients with borderline resectable pancreatic cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Autologous dendritic cells loaded with allogenic allogeneic lysate of mesothelioma cell lines
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Novartis Pharma AG

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Zampilimab
  • Sponsor:Chiesi Farmaceutici S.p.A.

Graft versus host disease

Not yet recruiting

Safety and Efficacy of MaaT013 with Vancomycin in Children and Adolescents with Gastrointestinal Acute Graft‑versus‑Host Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Vancomycin
  • Sponsor:Maat Pharma
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clemastine Fumarate
  • Sponsor:Amsterdam UMC Stichting

Non-small cell lung cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merus B.V.

Comparison of standard dosing and blood level monitoring of abiraterone acetate for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Acute lymphocytic leukaemia+1

Not yet recruiting

A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Amgen Inc.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Leiden

What the registry says about research in the country

01 Infectious Diseases Research

Innovative studies focusing on viral infections including trials evaluating vaccines against yellow fever, influenza, and mpox. Research includes assessment of antibody responses and vaccine effectiveness in different populations.

  • Influenza vaccine efficacy in elderly
  • Yellow fever prophylaxis
  • Mpox booster vaccination

Particular emphasis on preventive strategies and immune response evaluation.

02 Neurological Studies

Comprehensive research targeting neurological conditions, including investigations into Parkinson's disease treatments and neural response patterns. Studies examine innovative therapeutic approaches.

  • Parkinson's Disease treatments
  • CNS response analysis
  • Cerebral Amyloid Angiopathy

Focus on developing targeted therapies and understanding brain mechanisms.

03 Cancer and Chronic Conditions

Advanced research in oncology and chronic diseases, including studies on gastric cancer imaging and T-cell lymphoma treatments. Investigations into kidney disease management.

  • Advanced solid tumors
  • Gastric cancer diagnosis
  • Chronic kidney disease

Emphasis on innovative diagnostic techniques and treatment approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.